Jupiter Neurosciences and Catalent Partner to produce JOTROL softgel capsules

Jupiter Neurosciences Inc., a pharmaceutical company in the clinical stage, is developing JOTROL, a patented platform based on resveratrol, and has reached an agreement with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules to assist Jupiter's forthcoming Phase 2a clinical trial for Parkinson’s disease.

As per the agreement, Catalent will produce clinical batches of JOTROL, Jupiter's exclusive resveratrol-based therapy, utilizing an enhanced softgel formulation. The study on Parkinson's will comprise both active and placebo batches in its production.

“Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson’s disease,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Catalent’s industry-leading expertise in pharmaceutical manufacturing and its ability to scale production efficiently according to a tight timeline will help us maintain momentum in our development program and support our goal of delivering innovative therapies to patients.”

The forthcoming Phase 2a study will assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of JOTROL in patients with Parkinson’s disease over a duration of three months.

Jupiter Neurosciences Inc is a pharmaceutical firm focused on clinical stage research and development based in the USA. The company has created a distinctive resveratrol platform product mainly focused on addressing neuro-inflammation treatment. Its platform product, JOTROL, provides possible therapeutic advantages for various central nervous system conditions, including Alzheimer's disease, ataxias, and metabolic disorders like Lysosomal Storage Disorders and mitochondrial diseases.